{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-24-003933","form_type":"8-K","ticker":"CORT","cik":"0001088856","company_name":"CORCEPT THERAPEUTICS INC","filed_at":"2024-01-08T23:59:59+00:00","discovered_at":"2026-05-14T18:03:23.332832+00:00","generated_at":"2026-06-07T01:57:54.186664+00:00","sec_items":["2.02","8.01","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Corcept reports Q4 2023 revenue $135.4M (+31% YoY); guides 2024 rev $600-630M; announces $200M buyback","bullets":["Q4 2023 revenue $135.4M, up 31% YoY from $103.1M; full year $482.4M, up 20% from $401.9M.","2024 revenue guidance $600-630 million; cash and investments $425.4M at Dec 31, 2023.","Board authorized $200M stock repurchase program; effective Jan 10, 2024.","Results are preliminary, unaudited, and subject to audit adjustments."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-24-003933","json":"https://secwatch.observer/filing/0001193125-24-003933.json","markdown":"https://secwatch.observer/filing/0001193125-24-003933.md","text":"https://secwatch.observer/filing/0001193125-24-003933.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1088856/000119312524003933/0001193125-24-003933-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1088856/000119312524003933/d45395d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-07T01:57:54.186664+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"023467ce0a4e2a2a0aee84ed64d77b40914e4629","claim":"CORCEPT THERAPEUTICS INC reported year ended December 31, 2023 results: revenue $482.4 million.","evidence_excerpt":"Full year 2023 revenue of $482.4 million, a 20 percent increase over 2022","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1088856/000119312524003933/0001193125-24-003933-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"year ended December 31, 2023"},{"label":"Revenue","value":"$482.4 million"},{"label":"Result","value":"preliminary results"}],"fact_type":"earnings_release"},{"claim_id":"22892900bbb5a34abc74172d3bbd32253faba723","claim":"CORCEPT THERAPEUTICS INC reported quarter ended December 31, 2023 results: revenue $135.4 million.","evidence_excerpt":"Fourth quarter revenue of $135.4 million, a 31 percent increase over the same period in 2022","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1088856/000119312524003933/0001193125-24-003933-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"quarter ended December 31, 2023"},{"label":"Revenue","value":"$135.4 million"},{"label":"Result","value":"preliminary results"}],"fact_type":"earnings_release"},{"claim_id":"74bcf76427e4a4bd05dccabf7f6f3d6d29aa4808","claim":"CORCEPT THERAPEUTICS INC reported fiscal year 2024 results: revenue $600 – $630 million. Guidance initiated.","evidence_excerpt":"Financial Update • Fourth quarter revenue of $135.4 million, a 31 percent increase over the same period in 2022 • Full year 2023 revenue of $482.4 million, a 20 percent increase over 2022 • 2024 revenue guidance of $600 – $630 million • Cash and investments of $425.4 million as of December 31, 2023 • Announcement of $200 million stock repurchase program “As the true prevalence of hypercortisolism and its devastating impact become better understood, physicians are identifying and treating more patients","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1088856/000119312524003933/0001193125-24-003933-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"fiscal year 2024"},{"label":"Revenue","value":"$600 – $630 million"},{"label":"Guidance","value":"initiated"},{"label":"Result","value":"guidance update"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}